-- Can Fite Poised for Biggest Gain Since November
-- B y   G w e n   A c k e r m a n
-- 2012-02-22T12:20:05Z
-- http://www.bloomberg.com/news/2012-02-22/can-fite-poised-for-biggest-gain-since-november-correct-.html
(Corrects share price in second paragraph.)  Can Fite Biopharma (CFBI)  Ltd. headed for
the biggest gain since November after the the U.S.  Food and Drug
Administration  gave its CF102 drug to treat primary liver cancer
orphan status.  The shares soared 7.6 percent, the most since Nov. 6, to
0.479 shekels at 1:12 p.m. in  Tel Aviv . That gave the company a
market value of 125 million shekels ($33 million).  To contact the reporter on this story:
Gwen Ackerman in Jerusalem at 
 gackerman@bloomberg.net   To contact the editor responsible for this story:
Claudia Maedler at 
 cmaedler@bloomberg.net  